The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMercia Asset Regulatory News (MERC)

Share Price Information for Mercia Asset (MERC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.70
Bid: 32.00
Ask: 33.40
Change: 0.00 (0.00%)
Spread: 1.40 (4.375%)
Open: 32.70
High: 32.70
Low: 32.70
Prev. Close: 32.70
MERC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Mercia Asset Management (MERC): The UK's top regional investor

3 Mar 2021 07:00

Edison Investment Research Limited Edison Investment Research Limited: Mercia Asset Management (MERC): The UK's top regional investor 03-March-2021 / 07:00 GMT/BST


 

London, UK, 3 March 2021

 

Mercia Asset Management (MERC): The UK's top regional investor

The £30.7m cash exit from Oxgene underlines management's success in building a sustainably profitable specialist asset manager, delivering high levels of contracted revenue and providing a filtered pipeline of opportunities for Mercia's direct investment portfolio. Based on progress to date, we believe Mercia will achieve its three-year strategic plan ahead of time (grow operating profitability, expand assets under management (AUM) to £1bn and 'evergreen' the balance sheet by end FY22). By the end of H121, AUM had risen to £872m (15% from FY22 target), with fee-earning funds under management (FUM) of £722m. Despite progress, Mercia's shares continue to trade at a material 21% discount to net assets (0.79x) or a 30-35% discount when we include the third-party funds business (worth 4.9p at 3% of FUM). This is a substantial discount to its peers.

 

Although profitable and dividend paying, with a mature, evergreen balance sheet, and scaling AUM, Mercia still trades at a 21% discount to its H121 NAV (34.1p per share) and a significant discount to its peers. Together with its fund management arm (5-8p per share), the overall valuation rises to 39-42p per share, implying a discount of closer to 31-36%. Catalysts for a re-rating include further scaling of the business, continuing revenue/earnings growth, commercialisation of the direct investment portfolio and/or successful exits.  

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Richard Williamson +44 (0)20 3077 5700 tech@edisongroup.com

Rob Murphy +44 (0)20 3077 5700 tech@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1172526 03-March-2021 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
20th Dec 201910:29 amRNSResult of General Meeting
9th Dec 20192:05 pmRNSSecond Price Monitoring Extn
9th Dec 20192:00 pmRNSPrice Monitoring Extension
5th Dec 20197:00 amRNSPosting of documents and Notice of GM
3rd Dec 20193:46 pmRNSResult of Accelerated Bookbuild to raise £30.0m
3rd Dec 20199:05 amRNSSecond Price Monitoring Extn
3rd Dec 20199:00 amRNSPrice Monitoring Extension
3rd Dec 20197:01 amRNSProposed Acquisition & ABB to raise £30.0million
3rd Dec 20197:00 amRNSHalf Year Results
20th Nov 20197:00 amRNSnDreams makes significant commercial progress
14th Nov 20197:00 amRNSAppointment of Joint Broker
5th Nov 201911:02 amRNSNotification of Major Holdings
4th Nov 20194:49 pmRNSNotification of Major Holdings
1st Nov 20194:31 pmRNSNotification of Major Holdings
22nd Oct 20194:54 pmRNSNotification of Major Holdings
17th Oct 20191:59 pmRNSNotification of Major Holdings
16th Oct 20197:36 amRNSNotification of Major Holdings
25th Sep 20197:00 amRNSAnnouncement of significant contract for OXGENE
24th Sep 201911:02 amRNSResult of AGM
24th Sep 20197:00 amRNSAGM Statement
10th Sep 20197:00 amRNS£7.5million syndicated investment into Voxpopme
1st Aug 20197:00 amRNSGrant of Options
29th Jul 20192:24 pmRNSNotification of Major Holdings
26th Jul 20197:00 amRNSPublication of Annual Report
8th Jul 20197:00 amRNSPreliminary Results
5th Jul 201910:00 amRNSChange of Name
2nd Jul 20197:00 amRNSDirectorate Change
21st May 20197:00 amRNS£2.4million syndicated investment into Medherant
15th May 20197:00 amRNS£2.0million syndicated investment into Locate Bio
14th May 20197:06 amRNSConcepta PLC confirms first myLotus® pregnancies
2nd May 20197:00 amRNSNotice of Preliminary Results
11th Apr 20199:41 amRNSPDMR Dealing
10th Apr 20197:00 amRNSDirector/ PDMR Dealings
28th Mar 20197:00 amRNS£6.5m syndicated investment into Oxford Genetics
18th Mar 20194:23 pmRNSPDMR / Director Dealings
15th Mar 20191:19 pmRNSPDMR / Director Dealings
12th Mar 20197:06 amRNSPortfolio company Concepta secures partnership
28th Feb 20197:00 amRNSPortfolio company announces six licensing deals
20th Feb 20197:00 amRNSSoftware & the Internet Portfolio Update
5th Feb 20197:00 amRNSAppointment of NOMAD
3rd Dec 20187:00 amRNSHalf Year Results
31st Oct 20187:00 amRNSNotice of Results
29th Oct 20187:00 amRNSNew Direct Investment in W2 Global Data Solutions
18th Oct 20187:00 amRNSCapital Markets Day
16th Oct 20187:00 amRNSNew Emerging Star investment into Locate Bio
21st Sep 201810:47 amRNSResult of AGM
21st Sep 20187:00 amRNSAGM Statement
18th Sep 20187:00 amRNSAston EyeTech secures multi-million pound contract
13th Sep 20187:00 amRNSNotice of Capital Markets Day
29th Aug 20187:00 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.